Morgan Stanley maintains Attovia Therapeutics at Overweight, raises price target to $40 from $39

Morgan Stanley kept its Overweight rating on Attovia Therapeutics and increased its price target to $40 from $39, a 2.6% rise. This target suggests a 150.6% upside from the Nov 9 closing price of $15.96, according to the firm.

Original reporting
Published Nov 10, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Attovia Therapeutics at Overweight, raises price target to $40 from $39 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The rating lift could prompt short‑term buying, but without substantive catalyst the move may be limited.

02

Market read

Analyst upgrade provides a modest trading signal for ATVA.

03

What to watch

No new product data or regulatory milestones accompany the upgrade.

Relevance 5/10Novelty 4/10Timing: pre-market today

Background

Attovia Therapeutics is a clinical‑stage biotech focused on rare diseases.

Market effects

May lift sentiment in the small‑cap biotech sector.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

The target increase is modest and may already be priced in; caution on over‑optimism.

Key entities

  • Morgan Stanley

    Equity research firm that issued the rating upgrade.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOHighAI 9/10

Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

$ATTOMedAI 8/10

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

$ATTOMedAI 8/10

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.